Great post. And your point ”… as well as an additional scan to try and detect non PSMA expressing lesions (such as this product).”
That could be a Cu64-SAR bisPSMA followed by Bombesin scan - double revenues to Clairty but you can detect most (all?) lesions and be doubly sure you haven’t missed any. Who wouldn’t want that?
CU6 Price at posting:
$2.32 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)